Synthetic biology startup StrainX Bioworks has secured $13 million in a fresh funding round co-led by early-stage venture capital firms Prime Venture Partners and Leo Capital. The round also saw participation from a cluster of institutional and angel investors, including Good Startup, Sparrow Capital, Sun Icon Ventures, Dhoka Ventures, and WTF (India) Delhi Angels.
The Bengaluru-headquartered firm plans to deploy the capital to expand its research and development capabilities, build larger fermentation infrastructure, and grow its engineering and scientific teams. A significant portion of the capital will also back its initial commercialisation efforts across international borders.
About Company
Bengaluru-based startup was founded in 2023 by Akshay Mittal and Alok Malaviya, StrainX Bioworks has spent the last two years operating in stealth mode. During this period, the company focused on building capabilities across strain engineering, fermentation process scale-up, and product development. The startup develops proprietary enzymes, proteins, and metabolites tailored for the food, healthcare, and agriculture sectors, with a core focus on alternative proteins.
Synthetic biology involves engineering microbes to produce specific molecules that are traditionally sourced from plants or animals. These microorganisms are grown inside industrial fermentation systems to manufacture ingredients in highly controlled environments. While the pharmaceutical industry has relied on these biological systems for decades, a steep decline in production costs is driving its application in food, nutrition, and consumer goods.
We have spent the past two years proving our biological systems can perform outside the lab.— Alok Malaviya, Co-founder, StrainX Bioworks
"Our platform integrates biotechnology, fermentation infrastructure, process engineering, and product development into a single system. The primary goal is to accelerate the transition from scientific discovery to industrial-scale manufacturing, making the alternative protein supply chain commercially viable," said Akshay Mittal, Co-founder of StrainX Bioworks.
Capital Expenditure
The alternative protein space in India has faced a steep climb, primarily due to the high capital expenditure required for setting up bioreactors and the technical challenges of maintaining consistency at scale. Many deep-tech startups struggle with a cash leak during the transition from laboratory trials to commercial production.
StrainX Bioworks claims to have bypassed some of these early bottlenecks. The company stated that it has already demonstrated precision fermentation at a 10,000-litre scale. The fresh capital is expected to provide the financial mettle needed to scale production beyond this pilot phase as it eyes commercial entry into competitive overseas markets, including the United States.
"We have validated our process at the 10,000-litre mark, and our current focus is on scaling production further as we prepare for commercialisation in India and overseas markets," noted Alok Malaviya, Co-founder of StrainX Bioworks.
Investor interest in synthetic biology remains steady despite a broader slowdown in late-stage tech funding. Early-stage backers are increasingly looking for deep-tech platforms that own proprietary intellectual property and offer clear pathways to industrial scale.
Global Market
The global demand for sustainable food ingredients has seen skyrocketing growth, driven by climate concerns and supply chain vulnerabilities. However, for Indian synthetic biology players, domestic success hinges on lowering production costs to match traditional agricultural pricing. By targeting high-value food ingredients and enzymes alongside alternative proteins, StrainX Bioworks is attempting to balance its margins early in the production cycle.
With validation at the pilot stage complete, the next phase for the startup involves securing regulatory approvals in international markets like the US, where the compliance framework for precision fermentation is more established than in India. The capital infusion establishes a longer runway for the company to navigate these regulatory timelines and build out its commercial distribution channels.
